BioCentury
ARTICLE | Clinical News

PBT-1: Phase II updated data

April 26, 2004 7:00 AM UTC

Results from a 48-week extension of a previously reported 36-week Phase II trial showed that PBT-1 slowed decline in cognitive function. The longer-term treatment was well tolerated. Data were present...